What is Prother^®?

The special and unique WPI of Prother^® are called DIF16WPI^®, it is an undenatured whey protein isolate concentrate with a high content of cysteine (2,7%).

WPI are the purest form of serum proteins, which are the quantitatively second most important fraction of milk, including for instance β-lactoglobulin, α-lactalbumin, immunoglobulins, glycomacropeptide, serum albumin and lactoferrin..

DIF16WPI^® are extracted through a manufacturing process of microfiltration on the membrane, followed by a low temperature spray-drying treatment that guarantees:

• - intact proteins with a high biological value (BV 104)
• - high pureness of the concentrate, proteins ≥ 92,5%
• - 1 sachet brings only 36.4 Kcal
• - Low content of fat (≤ 1%)
• - Low content of lactose (≤ 1 %) that makes it suitable for lactose intolerants.

Sarcopenia can be defined as a geriatric syndrome characterized initially by loss of muscle mass destined to progress, which leads to deterioration in strength and physical performance [Brioche 2016]. Key topic in the treatment of sarcopenia is its close correlation with the frailty of the elderly, of which sarcopenia can be considered both as a starting point, and as the pathophysiological path through which the negative effects of fragility are manifested [Landi 2015].

The etiology of sarcopenia is not yet clearly defined, but it is commonly believed that there is not a single cause. Among the factors recognized as decisive must be mentioned [Brioche 2016]

• Diet
• Malnutrition and chronic diseases
• Physical inactivity
• Aging process

In light of the pathophysiological picture of sarcopenia, it is not difficult to identify two fundamental nutritional approaches for the support of patients who are affected, or who are in situations that expose them to this condition:

• An adequate protein intake to support muscle anabolism
• Whey protein with high cysteine content

REFERENCES
Brioche T, Lemoine-Morel S. Oxidative Stress, Sarcopenia, Antioxidant Strategies and Exercise: Molecular Aspects. Curr Pharm Des. 2016;22(18):2664-78.

Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R, Onder G, Marzetti E. Sarcopenia as the Biological Substrate of Physical Frailty. Clin Geriatr Med. 2015 Aug;31(3):367-74.

Foods for Special Medical Purposes (A.F.M.S.) are formulations realised for the diet of subjects with particular disorders or suffering from diseases. They are regulated by Directive 99/21/CE, nationally implemented with the presidential decree of 20th March 2002, n. 57 and subject to the notification procedure of the Ministry of Health.

“Regulation (UE) 609/2013 (art. 2.2.g) reinstates their definition: “a food product explicitly developed or formulated and realised for the diet management of patients, including infants, to be used under medical control; it is intended for the complete or partial nutrition of patients with a limited, disturbed or altered ability to take, digest, absorb, metabolize or eliminate common foods or certain nutrients contained in them or metabolites, or with other nutritional needs caused by clinic conditions and the diet management of who can not be exclusively implemented modifying the normal diet.”

Ultimately these are products intended for the dietetic treatment of subjects suffering from disorders, diseases or medical conditions that determine a nutritional vulnerability, that is the impossibility or a great difficulty to feed using common foods, including food supplements, to satisfy their nutritional requirements.”

Ministry of Health